ASX-LISTED biopharma MGC Pharma has announced that Australians suffering from drug-resistant epilepsy will be able to access a new medical marijuana-based treatment by Dec this year.
Following recent Human Research Ethics Committee endorsement from St Vincent's Hospital Melbourne for the use of MGC's CannEpil in the treatment of adult patients with drug-resistant epilepsy, the Therapeutic Goods Administration has approved the product.
MGC Pharmaceuticals co-founder and MD Roby Zomer said, "We are delighted to announce the availability of our first product CannEpil for supply under the Authorised Prescriber Scheme.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Oct 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Oct 18
